Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

In the Claims:

What is claimed is:

1. (Original) A pharmaceutical formulation comprising: (a) an effective amount of levothyroxine sodium, (b) microcrystalline cellulose which has a mean particle size of less than 125μm and is present in an amount of 60 to 85% w/w based upon the total weight of the formulation, and (c) pregelatinised starch present in an amount of 5 to 30% w/w based upon total weight of the formulation.

2. (Previously Amended) The pharmaceutical formulation as claimed in claim 1 wherein the microcrystalline cellulose has a mean particle size less than or equal to 100μm.

3. (Previously Amended) The pharmaceutical formulation as claimed in claim 2 wherein the ratio of microcrystalline cellulose:pregelatinised starch is in the range of 2:1 to 15:1.

4. (Previously Amended) The pharmaceutical composition as claimed in claim 3 wherein the microcrystalline cellulose and pregelatinised starch comprise water which is present in an amount 3-6% w/w based on the total weight of the formulation.

5. (Previously Amended) The pharmaceutical formulation as claimed in claim 1 wherein the levothyroxine sodium is hydrated.

6. (Previously Amended) The pharmaceutical formulation as claimed in claim 5 wherein the levothyroxine sodium is the pentahydrate form.

7. (Previously Amended) The pharmaceutical formulation as claimed in claim 1 which further comprises one or more glidant/lubricants.

8. (Previously Amended) The pharmaceutical formulation as claimed in claim 7 wherein the glidant/lubricants are selected from the group consisting of colloidal anhydrous silica, talc, magnesium stearate, and mixtures thereof.

9. (Previously Amended) The pharmaceutical formulation as claimed in claim 1 which is stable to the extent that potency decreases by less than 5% when the pharmaceutical formulation is stored at 25°C and 60% relative humidity for 12 months.

10. (Previously Amended) The pharmaceutical formulation as claimed in claim 1 in unit dose form.

11. (Previously Amended) The pharmaceutical formulation as claimed in claim 10 wherein the unit dose form is a tablet.

12. (Cancelled).

13. (Cancelled).

14. (Cancelled).

15. (Previously Amended) A method of treating thyroid hormone disorders comprising administering a pharmaceutical formulation as claimed in claim 1 to a mammal.

16. (Previously Amended) A process for preparing a pharmaceutical formulation as claimed in claim 1 comprising (a) preparing a triturate of levothyroxine sodium, (b) mixing the triturate with the remaining components of the pharmaceutical formulation, and (c) compression.

17. (Previously Added) The method of claim 15 wherein said mammal is a human.